tirzepatide discontinuation weight regain Trajectory of the body after drug in the treatment of anti-obesity medications | BMC Medicine nference | What happens to

Persistence and Adjacent Indications Persistence or the length of time patients stayed on GLP-1s also varied by patients overall disease burden, weight loss and HbA1c measures at initiation

Even though I have a great space for having people over, I rarely had parties, she admits

12 (2), 537555 (2021) Johansen, P., Chubb, B., Hunt, B., Malkin, S.J.P., Sandberg, A., Capehorn, M.: Evaluating the long-term cost-effectiveness of once-weekly semaglutide vs

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, randomly assigned 751 adults with obesity to either tirzepatide or semaglutide for 72 weeks.[1] The results were clear: Average weight loss with tirzepatide: 20.2% Average weight loss with semaglutide: 13.7% Tirzepatide patients were also more likely to hit major milestones 10%, 15%, 20%, and even 25% body weight loss

At a Se intake of 70 g/day, the predicted plasma Se concentrations would be ~ 100110 g/L (51), and by taking 200 g/day of Se, roughly all adults would have plasma Se levels above 100 g/L after several months